Acta Neurochirurgica

, Volume 157, Issue 11, pp 1983–1990 | Cite as

Factors influencing the growth rate of vestibular schwannoma in patients with neurofibromatosis type 2

  • Huan Li
  • Shu-Yu Hao
  • Liang Wang
  • Da Li
  • Zhen Wu
  • Li-Wei Zhang
  • Jun-Ting Zhang
Clinical Article - Brain Tumors

Abstract

Background

Neurofibromatosis type 2 (NF2) is a devastating disease with no well-accepted management guidelines. Better understanding of the disease process provides the basis for how or when to initiate treatment. Only few studies have addressed the factors influencing the growth rate of NF2-related vestibular schwannomas (VSs), and these studies have reported variable results. This study aimed to assess the clinical factors influencing the growth rate of NF2-related VSs.

Methods

The medical records of 66 patients (totalling 74 VSs) were retrospectively analysed. The tumours were measured according to a two-component box model. The tumour growth rate was estimated by linear regression analysis of the changes in VS volumes over time. The clinical characteristics of all the patients were recorded. The relationship between the tumour growth rate and clinical factors were analysed. Linear regression, Pearson’s correlation and Student’s t-test were conducted using the SPSS 19.0 statistical package.

Results

The median follow-up duration was 4.9 years. The VSs growth rate was highly correlated with the initial VS volume (r = 0.97, p < 0.01). However, it was inversely correlated with the age at symptom onset (r = −0.41, p < 0.01). The average VS growth rate in patients with spinal tumours was 13.18 cm3/year compared with 0.19 cm3/year in patients without spinal tumours (p < 0.01). The VS growth rate in patients who had resection of a contralateral VS was slightly higher than that of patients with untreated VSs (p < 0.01). Other factors including sex, vestibular symptom, presence of other cranial schwannomas, family history and dermal abnormalities did not affect the VS growth rate.

Conclusions

The potential clinical factors influencing the VS growth rate are the age at symptom onset, initial tumour volume and presence of spinal tumours. Surgical resection of VSs might accelerate the growth rate of contralateral tumours. The effects of these factors require further experimental confirmation.

Keywords

Neurofibromatosis type 2 Vestibular schwannoma Tumour growth 

Notes

Conflict of interest

None

References

  1. 1.
    Abaza MM, Makariou E, Armstrong M, Lalwani AK (1996) Growth rate characteristics of acoustic neuromas associated with neurofibromatosis type 2. Laryngoscope 106:694–699CrossRefPubMedGoogle Scholar
  2. 2.
    Aboukais R, Baroncini M, Zairi F, Bonne NX, Schapira S, Vincent C, Lejeune JP (2013) Prognostic value and management of spinal tumors in neurofibromatosis type 2 patients. Acta Neurochir (Wien) 155:771–777CrossRefGoogle Scholar
  3. 3.
    Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, Lonser RR (2009) Neurofibromatosis type 2. Lancet 373:1974–1986CrossRefPubMedGoogle Scholar
  4. 4.
    Baser ME, Makariou EV, Parry DM (2002) Predictors of vestibular schwannoma growth in patients with neurofibromatosis type 2. J Neurosurg 96:217–222CrossRefPubMedGoogle Scholar
  5. 5.
    Baser ME, Mautner VF, Parry DM, Evans DG (2005) Methodological issues in longitudinal studies: vestibular schwannoma growth rates in neurofibromatosis 2. J Med Genet 42:903–906PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Blakeley JO, Evans DG, Adler J, Brackmann D, Chen R, Ferner RE, Hanemann CO, Harris G, Huson SM, Jacob A, Kalamarides M, Karajannis MA, Korf BR, Mautner VF, McClatchey AI, Miao H, Plotkin SR, Slattery W, Stemmer-Rachamimov AO, Welling DB, Wen PY, Widemann B, Hunter-Schaedle K, Giovannini M (2012) Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A 158A:24–41PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Choi JW, Lee Jy F, Phi JH, Phi Jh F, Wang K-C, Wang Kc F, Chung H-T, Chung H, Paek SH F, Paek Sh F, Kim DG (2014) Clinical course of vestibular schwannoma in pediatric neurofibromatosis type 2. J Neurosurg Pediatr 13(6):650–657CrossRefPubMedGoogle Scholar
  8. 8.
    Dang M, Modi J, Roberts M, Chan C, Mitchell JR (2013) Validation study of a fast, accurate, and precise brain tumor volume measurement. Comput Methods Prog Biomed 111:480–487CrossRefGoogle Scholar
  9. 9.
    Dirks MS, Butman JA, Kim HJ, Wu T, Morgan K, Tran AP, Lonser RR, Asthagiri AR (2012) Long-term natural history of neurofibromatosis type 2-associated intracranial tumors. J Neurosurg 117:109–117CrossRefPubMedGoogle Scholar
  10. 10.
    Dow G, Biggs N, Evans G, Gillespie J, Ramsden R, King A (2005) Spinal tumors in neurofibromatosis type 2. Is emerging knowledge of genotype predictive of natural history? J Neurosurg Spine 2:574–579CrossRefPubMedGoogle Scholar
  11. 11.
    Evans DG (2009) Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 4:16PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Evans DG, Baser ME, O’Reilly B, Rowe J, Gleeson M, Saeed S, King A, Huson SM, Kerr R, Thomas N, Irving R, MacFarlane R, Ferner R, McLeod R, Moffat D, Ramsden R (2005) Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg 19:5–12CrossRefPubMedGoogle Scholar
  13. 13.
    Evans DG, Bowers N, Huson SM, Wallace A (2013) Mutation type and position varies between mosaic and inherited NF2 and correlates with disease severity. Clin Genet 83:594–595CrossRefPubMedGoogle Scholar
  14. 14.
    Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Strachan T, Harris R (1992) A genetic study of type 2 neurofibromatosis in the United Kingdom II. Guidelines for genetic counselling. J Med Genet 29:847–852PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Strachan T, Ramsden R, Harris R (1992) A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 29:841–846PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Evans DG, Kalamarides M, Hunter-Schaedle K, Blakeley J, Allen J, Babovic-Vuskanovic D, Belzberg A, Bollag G, Chen R, DiTomaso E, Golfinos J, Harris G, Jacob A, Kalpana G, Karajannis M, Korf B, Kurzrock R, Law M, McClatchey A, Packer R, Roehm P, Rubenstein A, Slattery W, Tonsgard JH, Welling DB, Widemann B, Yohay K, Giovannini M (2009) Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res 15:5032–5039PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Evans DG, Wallace A (2009) An update on age related mosaic and offspring risk in neurofibromatosis 2 (NF2). J Med Genet 46:792CrossRefPubMedGoogle Scholar
  18. 18.
    Fukuda M, Oishi M, Hiraishi T, Natsumeda M, Fujii Y (2011) Clinicopathological factors related to regrowth of vestibular schwannoma after incomplete resection. J Neurosurg 114:1224–1231PubMedGoogle Scholar
  19. 19.
    Goutagny S, Bah AB, Henin D, Parfait B, Grayeli AB, Sterkers O, Kalamarides M (2012) Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features. Neuro Oncol 14:1090–1096PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Ito E, Saito K, Yatsuya H, Nagatani T, Otsuka G (2009) Factors predicting growth of vestibular schwannoma in neurofibromatosis type 2. Neurosurg Rev 32:425–433CrossRefPubMedGoogle Scholar
  21. 21.
    Jalayer Naderi N, Tirgari F, Esmaili F, Paktinat F, Keshavarz Z (2012) Vascular endothelial growth factor and ki-67 antigen expression in relation to age and gender in oral squamous cell carcinoma. J Dent Res Dent Clin Dent Prospects 6:103–107PubMedCentralPubMedGoogle Scholar
  22. 22.
    Lassaletta L, Torres-Martin M, Pena-Granero C, Roda JM, Santa-Cruz-Ruiz S, Castresana JS, Gavilan J, Rey JA (2013) NF2 genetic alterations in sporadic vestibular schwannomas: clinical implications. Otol Neurotol 34:1355–1361CrossRefPubMedGoogle Scholar
  23. 23.
    Mathieu D, Kondziolka D, Flickinger JC, Niranjan A, Williamson R, Martin JJ, Lunsford LD (2007) Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates. Neurosurgery 60:460–468, discussion 468–470 PubMedGoogle Scholar
  24. 24.
    Mautner VF, Baser ME, Thakkar SD, Feigen UM, Friedman JM, Kluwe L (2002) Vestibular schwannoma growth in patients with neurofibromatosis type 2: a longitudinal study. J Neurosurg 96:223–228CrossRefPubMedGoogle Scholar
  25. 25.
    Nutik SL, Babb MJ (2001) Determinants of tumor size and growth in vestibular schwannomas. J Neurosurg 94:922–926CrossRefPubMedGoogle Scholar
  26. 26.
    Odat HA, Piccirillo E, Sequino G, Taibah A, Sanna M (2011) Management strategy of vestibular schwannoma in neurofibromatosis type 2. Otol Neurotol 32:1163–1170CrossRefPubMedGoogle Scholar
  27. 27.
    Peyre M, Goutagny S, Bah A, Bernardeschi D, Larroque B, Sterkers O, Kalamarides M (2013) Conservative management of bilateral vestibular schwannomas in neurofibromatosis type 2 patients: hearing and tumor growth results. Neurosurgery 72:907–913, discussion 914; quiz 914 CrossRefPubMedGoogle Scholar
  28. 28.
    Peyre M, Goutagny S, Imbeaud S, Bozorg-Grayeli A, Felce M, Sterkers O, Kalamarides M (2011) Increased growth rate of vestibular schwannoma after resection of contralateral tumor in neurofibromatosis type 2. Neuro Oncol 13:1125–1132PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Phi JH, Kim DG, Chung HT, Lee J, Paek SH, Jung HW (2009) Radiosurgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2: tumor control and hearing preservation. Cancer 115:390–398CrossRefPubMedGoogle Scholar
  30. 30.
    Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG 2nd (2012) Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 33:1046–1052CrossRefPubMedGoogle Scholar
  31. 31.
    Plotkin SR, Merker VL, Muzikansky A, Barker FG 2nd, Slattery W 3rd (2014) Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients. Otol Neurotol 35:e50–56CrossRefPubMedGoogle Scholar
  32. 32.
    Plotkin SR, O’Donnell CC, Curry WT, Bove CM, MacCollin M, Nunes FP (2011) Spinal ependymomas in neurofibromatosis type 2: a retrospective analysis of 55 patients. J Neurosurg Spine 14:543–547CrossRefPubMedGoogle Scholar
  33. 33.
    Rosenberg SI, Silverstein H, Gordon MA, Flanzer JM, Willcox TO, Silverstein J (1993) A comparison of growth rates of acoustic neuromas: nonsurgical patients vs. Subtotal resection. Otolaryngol Head Neck Surg 109:482–487PubMedGoogle Scholar
  34. 34.
    Saito K, Kato M, Susaki N, Nagatani T, Nagasaka T, Yoshida J (2003) Expression of Ki-67 antigen and vascular endothelial growth factor in sporadic and neurofibromatosis type 2-associated schwannomas. Clin Neuropathol 22:30–34PubMedGoogle Scholar
  35. 35.
    Slattery WH 3rd, Fisher LM, Iqbal Z, Oppenhiemer M (2004) Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects. Otol Neurotol 25:811–817CrossRefPubMedGoogle Scholar
  36. 36.
    Suryanarayanan R, Ramsden RT, Saeed SR, Aggarwal R, King AT, Rutherford SA, Evans DG, Gillespie JE (2010) Vestibular schwannoma: role of conservative management. J Laryngol Otol 124:251–257CrossRefPubMedGoogle Scholar
  37. 37.
    Tanaka Y, Hongo K, Tada T, Sakai K, Kakizawa Y, Kobayashi S (2003) Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patient age, and MIB-1 index. J Neurosurg 98:359–365CrossRefPubMedGoogle Scholar
  38. 38.
    Torres-Martín M, Martinez-Glez V, Peña-Granero C, Lassaletta L, Isla A, de Campos JM, Pinto GR, Burbano RR, Meléndez B, Castresana JS, Rey JA (2013) Expression analysis of tumor-related genes involved in critical regulatory pathways in schwannomas. Clin Transl Oncol 15:409–411CrossRefPubMedGoogle Scholar
  39. 39.
    Tysome JR, Macfarlane R, Durie-Gair J, Donnelly N, Mannion R, Knight R, Harris F, Vanat ZH, Tam YC, Burton K, Hensiek A, Raymond FL, Moffat DA, Axon PR (2012) Surgical management of vestibular schwannomas and hearing rehabilitation in neurofibromatosis type 2. Otol Neurotol 33:466–472CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2015

Authors and Affiliations

  • Huan Li
    • 1
    • 2
  • Shu-Yu Hao
    • 2
  • Liang Wang
    • 2
  • Da Li
    • 2
  • Zhen Wu
    • 2
  • Li-Wei Zhang
    • 2
  • Jun-Ting Zhang
    • 2
  1. 1.Beijing Neurosurgical InstituteCapital Medical UniversityBeijingPeople’s Republic of China
  2. 2.Department of Neurosurgery, Beijing Tiantan HospitalCapital Medical UniversityBeijingPeople’s Republic of China

Personalised recommendations